Author

K. H. Dinnon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:mouse· 8 Research Focus:drug response / drug discovery· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

S. R. Leist· 8 shared R. S. Baric· 6 shared K. L. Gully· 5 shared L. E. Gralinski· 5 shared A. West· 4 shared A. Schäfer· 3 shared B. L. Yount· 3 shared D. R. Martinez· 3 shared

Activity by Year

2017-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

S. R. Leist

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

J. Le Pen, G. Paniccia, V. Kinast, M. Moncada-Velez, A. W. Ashbrook, M. Bauer, H.- H. Hoffmann, A. Pinharanda, I. Ricardo-Lax, A. F. Stenzel, E. A. Rosado-Olivieri, K. H. Dinnon, W. C. Doyle, C. A. Freije, S.-H. Hong, , C. M. Rice

The paper identifies PLSCR1 as a host factor restricting SARS-CoV-2 entry, which recent variants have evolved to bypass, through a CRISPR screen and integration of genetic studies.

bioRxiv · Feb 16, 2024Immunology

Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination

L. E. Adams, S. R. Leist, K. H. Dinnon, A. West, K. L. Gully, E. Anderson, J. F. Loome, E. Madden, J. Powers, A. Schaefer, S. Sarkar, I. Castillo, J. Maron, R. P. McNamara, H. L. Bertera, , R. S. Baric

This study shows that non-neutralizing antibodies targeting FcR4 and spike S2 provide cross-protection against sarbecoviruses after alphavirus vector vaccination.

bioRxiv · Nov 28, 2022Microbiology

A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies

K. H. Dinnon, S. R. Leist, K. Okuda, H. Dang, E. J. Fritch, K. L. Gully, G. Cruz, M. D. Evangelista, T. Asakura, R. C. Gilmore, P. Hawkins, S. Nakano, A. West, A. Schäfer, L. E. Gralinski, , Montg

This paper develops a murine model of persistent post-SARS-CoV-2 lung disease to identify therapeutic targets and test interventions for PASC.

bioRxiv · Feb 15, 2022 · PreprintMicrobiology

SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo

Y. J. Hou, S. Chiba, P. Halfmann, C. Ehre, M. Kuroda, K. H. Dinnon, S. R. Leist, A. Schäfer, N. Nakajima, K. Takahashi, R. E. Lee, T. M. Mascenik, C. E. Edwards, L. V. Tse, R. C. Boucher, , R. S. Baric

This study shows the SARS-CoV-2 D614G variant replicates more efficiently and transmits faster in hamsters than the wildtype virus.

bioRxiv · Sep 28, 2020Microbiology

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

W. Sun, S. McCroskery, W.-C. Liu, S. R. Leist, Y. Liu, R. A. Albrecht, S. Slamanig, J. Oliva, F. Amanat, A. Schaefer, K. H. Dinnon, B. L. Innis, A. Garcia-Sastre, F. Krammer, R. S. Baric, P. Palese

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

bioRxiv · Jul 30, 2020Microbiology

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, , Wang

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

bioRxiv · Jun 11, 2020Immunology

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

K. H. Dinnon, S. R. Leist, A. Schafer, C. E. Edwards, D. R. Martinez, S. A. Montgomery, A. West, B. L. Yount, Y. J. Hou, L. E. Adams, K. L. Gully, A. J. Brown, E. Huang, M. D. Bryant, I. C. Choong, , R. S. Baric

This paper develops a mouse-adapted SARS-CoV-2 model to evaluate medical countermeasures, showing age-related disease severity and the efficacy of IFN lambda-1a.

bioRxiv · May 6, 2020Microbiology

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology

MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis

V. D. Menachery, L. E. Gralinski, H. D. Mitchell, K. H. Dinnon, S. R. Leist, B. L. Yount, R. L. Graham, E. T. McAnarney, K. G. Stratton, A. S. Cockrell, K. Debbink, A. C. Sims, K. M. Waters, R. S. Baric

This study shows that disrupting MERS-CoV NSP16's 2O methyl-transferase activity attenuates viral pathogenesis and provides a live attenuated vaccine platform.

bioRxiv · Aug 8, 2017Microbiology